Cti BioPharma
(NASDAQ) CTIC
This security has been delisted. This page is retained for historical reference.
CTIC News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowCTIC Financials
Key Financial Metrics (TTM)
Gross Margin
93.49%
Operating Margin
-147.91%
Net Income Margin
-168.76%
Return on Equity
1318.48%
Return on Capital
-246.43%
Return on Assets
-72.30%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$71.31M
Operating Income
-$53.93M
EBITDA
-$50.37M
Operating Cash Flow
-$82.32M
Capital Expenditure
$0.00
Free Cash Flow
-$82.32M
Cash & ST Invst.
$59.01M
Total Debt
$48.90M
Cti BioPharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$24.12M
+950.8%
Gross Profit
$22.89M
+1035.0%
Gross Margin
94.92%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
127
N/A
Net Income
-$21.80M
+41.4%
EBITDA
-$7.85M
+77.4%
Quarterly Fundamentals
Total Cash
$59.01M
-39.1%
Total Debt
$48.90M
+1.1%
Accounts Receivable
$22.96M
+846.3%
Inventory
$777.00K
+661.8%
Long Term Debt
$0.00
N/A
Short Term Debt
$48.08M
-0.5%
Return on Assets
-72.30%
N/A
Return on Invested Capital
-1.78%
N/A
Free Cash Flow
-$31.10M
-3.7%
Operating Cash Flow
-$31.10M
-3.7%